Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 1,171

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.

4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)

Open access
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Aguilar Lopez, B., Barrios, C.H., Bergh, J., Biganzoli, L., Boers-Doets, C.B., Cardoso, M.J., Carey, L.A., Cortés, J., Curigliano, G., Diéras, V., El Saghir, N.S., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Johnston, S.R.D., Kaufman, B., Koppikar, S., Krop, I.E., Mayer, M., Nakigudde, G., Offersen, B.V., Ohno, S., Pagani, O., Paluch-Shimon, S., Penault-Llorca, F., Prat, A., Rugo, H.S., Sledge, G.W., Spence, D., Thomssen, C., Vorobiof, D.A., Xu, B., Norton, L., Winer, E.P. · 2018 · Annals of Oncology

Abstract

Advanced Breast Cancer (ABC) comprises both locally advanced breast cancer (LABC) and metastatic breast cancer (MBC) [1]. Although treatable, MBC remains virtually an incurable disease with a median overall survival (OS) of ∼3years and a 5-year survival of only ∼25% [2, 3]. The MBC Decade Report [2] shows that progress has been slow in terms of improved outcomes, quality of life (QoL), awareness and information regarding ABC. More recently, some studies seem to indicate an improvement in OS, mostly due to advances in human epidermal growth factor receptor 2 (HER2)-positive ABC [4–6].

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/annonc/mdy192

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 14

  1. Masuda, 2011, Monthly versus 3-monthly goserelin acetate treatment in pre-menopausal patients with estrogen receptor-positive early breast cancer, Breast Cancer Res Treat, 126, 443, 10.1007/s10549-010-1332-y · doi:10.1007/s10549-010-1332-y
  2. Tabernero, 2017, Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers, ESMO Open, 1, e000142, 10.1136/esmoopen-2016-000142 · doi:10.1136/esmoopen-2016-000142
  3. Walsh, 2017, Oncofertility: fertile ground for conflict between patient autonomy and medical values, Oncologist, 22, 860, 10.1634/theoncologist.2016-0373 · doi:10.1634/theoncologist.2016-0373
  4. Tripathy, 2018, First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the randomized phase III MONALEESA-7 trial, Cancer Res, 78
  5. Di Leo, 2017, 236O_PR. MONARCH 3: abemaciclib as initial therapy for patients with HR+/HER2- advanced breast cancer, Ann Oncol, 28, mdx440.008
  6. Rugo, 2017, Abstract P6-11-12: subgroup analysis by prior treatment and disease burden in MONARCH 1: a phase 2 study of monotherapy abemaciclib, a CDK4 & 6 inhibitor, in patients with HR+/HER2- metastatic breast cancer (MBC) following chemotherapy, Cancer Res, 77, 11
  7. Gradishar, 2017, Phase III study of lapatinib (L) plus trastuzumab (T) and aromatase inhibitor (AI) vs T+AI vs L+AI in postmenopausal women (PMW) with HER2+, HR+ metastatic breast cancer (MBC): ALTERNATIVE, J Clin Oncol, 35, 1004, 10.1200/JCO.2017.35.15_suppl.1004 · doi:10.1200/jco.2017.35.15_suppl.1004
  8. Valencia, 2017, The role of genetic testing in patients with breast cancer: a review, JAMA Surg, 152, 589, 10.1001/jamasurg.2017.0552 · doi:10.1001/jamasurg.2017.0552
  9. Litton, 2015, A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA), J Clin Oncol, 33, TPS1107, 10.1200/jco.2015.33.15_suppl.tps1107 · doi:10.1200/jco.2015.33.15_suppl.tps1107
  10. Boothe, 2013, Bevacizumab as a treatment for radiation necrosis of brain metastases post stereotactic radiosurgery, Neuro Oncol, 15, 1257, 10.1093/neuonc/not085 · doi:10.1093/neuonc/not085
  11. Bollet, 2012, Preoperative radio-chemotherapy in early breast cancer patients: long-term results of a phase II trial, Radiother Oncol, 102, 82, 10.1016/j.radonc.2011.08.017 · doi:10.1016/j.radonc.2011.08.017
  12. Coles, 2017, Preoperative radiation therapy: the ‘new’ targeted breast cancer treatment?, Eur J Cancer, 78, 116, 10.1016/j.ejca.2017.03.027 · doi:10.1016/j.ejca.2017.03.027
  13. Bun, 2018, Symptom management: the utility of regional cooling for hand-foot syndrome induced by pegylated liposomal doxorubicin in ovarian cancer, Support Care Cancer, 26, 2161, 10.1007/s00520-018-4054-z · DOI
  14. Oliveira, 2017, OR135—effect of exercise on cardiovascular fitness and quality of life outcomes in advanced breast cancer patients, Breast, 36, S71, 10.1016/S0960-9776(17)30754-3 · doi:10.1016/s0960-9776(17)30754-3

Cited by

See all 1,171

Metadata

Authors
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Aguilar Lopez, B., Barrios, C. H., Bergh, J., Biganzoli, L., Boers-Doets, C. B., Cardoso, M. J., Carey, L. A., Cortés, J., Curigliano, G., Diéras, V., El Saghir, N. S., Eniu, A., Fallowfield, L., Francis, P. A., Gelmon, K., Johnston, S. R. D., Kaufman, B., Koppikar, S., Krop, I. E., Mayer, M., Nakigudde, G., Offersen, B. V., Ohno, S., Pagani, O., Paluch-Shimon, S., Penault-Llorca, F., Prat, A., Rugo, H. S., Sledge, G. W., Spence, D., Thomssen, C., Vorobiof, D. A., Xu, B., Norton, L., & Winer, E. P.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2018-08
Volume
29
Issue
8
Pages
1634-1657
ISSN
0923-7534 (ISSN-L)
OpenAlex
W4239051461
Cited by
1,171
References
59
FWCI
48.09
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.